Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Chan TK. The guiding principles for populational COVID-19 vaccine selection: A normative analysis through comparison of the strategies in Hong Kong and Singapore. J Glob Health 2022;12:03004. [PMID: 35265324 PMCID: PMC8877784 DOI: 10.7189/jogh.12.03004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open

For:	Chan TK. The guiding principles for populational COVID-19 vaccine selection: A normative analysis through comparison of the strategies in Hong Kong and Singapore. J Glob Health 2022;12:03004. [PMID: 35265324 PMCID: PMC8877784 DOI: 10.7189/jogh.12.03004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open

Number

Cited by Other Article(s)

Zhang Y, Zheng X, Sheng W, Liang H, Zhao Y, Zhu X, Yang R, Zhang Y, Dong X, Li W, Pei F, Ding L, Chang Z, Deng L, Yuan G, Yang Z, Zhu D, Yang X, Wang H. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. Vaccines (Basel) 2022;10:vaccines10081208. [PMID: 36016098 PMCID: PMC9413105 DOI: 10.3390/vaccines10081208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 07/20/2022] [Accepted: 07/26/2022] [Indexed: 11/16/2022] Open

Affiliation(s)

Yuntao Zhang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.) China National Biotec Group Company Limited, Beijing 100024, China
Xiaotong Zheng Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Wang Sheng College of Life Sciences and Biotechnology, Beijing University of Technology, Beijing 100021, China;
Hongyang Liang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Yuxiu Zhao Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Xiujuan Zhu Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Rong Yang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Yadan Zhang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Xiaofei Dong Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Weidong Li Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Fei Pei Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Ling Ding Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Zhen Chang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Li Deng Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Guangying Yuan Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Zhaona Yang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Di Zhu Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.)
Xiaoming Yang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.) China National Biotec Group Company Limited, Beijing 100024, China Correspondence: (X.Y.); (H.W.)
Hui Wang Beijing Institute of Biological Products Company Limited, Beijing 100176, China; (Y.Z.); (X.Z.); (H.L.); (Y.Z.); (X.Z.); (R.Y.); (Y.Z.); (X.D.); (W.L.); (F.P.); (L.D.); (Z.C.); (L.D.); (G.Y.); (Z.Y.); (D.Z.) Correspondence: (X.Y.); (H.W.)

Collapse

Chew MC, Wiryasaputra S, Wu M, Khor WB, Chan ASY. Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center. Front Med (Lausanne) 2022;9:925683. [PMID: 35814745 PMCID: PMC9265445 DOI: 10.3389/fmed.2022.925683] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 05/31/2022] [Indexed: 12/30/2022] Open

Abstract

Background

We report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.

Methods

Clinical data extracted from the de-identified uveitis database in Singapore National Eye Center. Six patients (eight eyes) developed uveitis within 14 days after undergoing COVID-19 vaccination (primary and/or booster).

Results

All patients received two doses of COVID-19 vaccination, and 1.39% (6/431) developed COVID-19 vaccine-related uveitis. Fifty-percent% (3/6) with non-infectious anterior uveitis (NIAU) presented with a non-granulomatous anterior uveitis (AU). The remaining (3/6) presenting with a granulomatous AU were diagnosed with reactivation of cytomegalovirus, varicella-zoster virus and toxoplasma chorioretinitis, respectively. All the patients responded to definitive treatment specific to their diagnosis. The mean visual acuity at presentation was 0.36 ± 0.20 logMAR and improved to 0.75 ± 0.09 (p = 0.009). Mean time from vaccination to uveitis was 9.7 (range: 3–14) days. All patients developed uveitis after second vaccination dose. 16.67% (1/6) patients had a recurrence after the third booster dose. None of the three patients with infectious uveitis developed recurrence but had received maintenance therapy up to or during the booster.

Conclusion

Uveitis after COVID-19 vaccination is uncommon. In our series, a higher rate of reactivations of latent infections was seen. With definitive treatment, all cases were self-limited without systemic sequelae. Prophylactic treatment during booster vaccine may prevent reactivation of sight-threatening infections and reduce morbidity although risk-benefits should be considered for individual patients given the low rate of occurrence.

Collapse